Oncology Drug Approval Decisions Expected in June 2024

In June, the FDA is expected to decide whether to approve tarlatamab for SCLC and imetelstat for MDS. In June, the FDA is expected to decide whether to approve tarlatamab for SCLC and imetelstat for MDS.

Related Keywords

, International Prognostic Scoring System , Drug Administration , Drug User Fee Act ,